About

Thing
Cofactor will automatically discover the description of this topic and display it here.

Mentions

At month end, the company’s PUR1900 ("Pulmazole") received the fast track designation from the FDA. The proprietary product is an inhaled itraconazole antifungal candidate being developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

See also

See also: